Lucatumumab

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Lucatumumab
DrugBank Accession Number
DB06360
Background

Not Available

Type
Biotech
Groups
Investigational
Synonyms
  • Lucatumumab
External IDs
  • CHIR-12.12
  • HCD-122
  • HCD122

Pharmacology

Indication

Investigated for use/treatment in leukemia (lymphoid), multiple myeloma, and lymphoma (unspecified).

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

HCD122 is a fully human, antagonist antibody that targets the CD40 antigen. HCD122 binds to tumor cells that express CD40 and antagonizes (prevents) CD40 ligand-mediated growth and survival of malignant B cells. Based on preclinical data, HCD122 also induces antibody-dependent cellular cytotoxicity (ADCC), killing CD40 expressing tumor cells by immune effector cells. This dual mechanism of action makes HCD122 a drug candidate with potential for the treatment of B-cell malignancies.

TargetActionsOrganism
UTumor necrosis factor receptor superfamily member 5Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbciximabThe risk or severity of adverse effects can be increased when Abciximab is combined with Lucatumumab.
AdalimumabThe risk or severity of adverse effects can be increased when Adalimumab is combined with Lucatumumab.
AducanumabThe risk or severity of adverse effects can be increased when Lucatumumab is combined with Aducanumab.
AlemtuzumabThe risk or severity of adverse effects can be increased when Alemtuzumab is combined with Lucatumumab.
AlirocumabThe risk or severity of adverse effects can be increased when Lucatumumab is combined with Alirocumab.
AmivantamabThe risk or severity of adverse effects can be increased when Lucatumumab is combined with Amivantamab.
AnifrolumabThe risk or severity of adverse effects can be increased when Lucatumumab is combined with Anifrolumab.
AnsuvimabThe risk or severity of adverse effects can be increased when Lucatumumab is combined with Ansuvimab.
Anthrax immune globulin humanThe risk or severity of adverse effects can be increased when Lucatumumab is combined with Anthrax immune globulin human.
Antilymphocyte immunoglobulin (horse)The risk or severity of adverse effects can be increased when Lucatumumab is combined with Antilymphocyte immunoglobulin (horse).
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
P0EP9VFC4R
CAS number
903512-50-5

References

General References
Not Available
Wikipedia
Lucatumumab

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedTreatmentFollicular Lymphoma ( FL)1
1CompletedTreatmentMultiple Myeloma (MM)1
1TerminatedTreatmentChronic Lymphocytic Leukemia (CLL)1
1, 2CompletedTreatmentLymphoma, Hodgkins / Non-Hodgkin's Lymphoma (NHL)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Ubiquitin protein ligase binding
Specific Function
Receptor for TNFSF5/CD40LG. Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion.
Gene Name
CD40
Uniprot ID
P25942
Uniprot Name
Tumor necrosis factor receptor superfamily member 5
Molecular Weight
30618.76 Da

Drug created on March 19, 2008 16:27 / Updated on February 21, 2021 18:52